Supplementary Figure S1. Flow chart of participant selection.
This flow chart illustrates the participant selection process from the Korean College of Rheumatology Biologics & Targeted Therapy registry (KOBIO). Initially, 2,916 patients were enrolled. After applying inclusion criteria, 2,453 patients were eligible. Subsequently, 303 patients lost to follow-up and 160 patients who withdrew consent were excluded. Ultimately, 185 patients experienced infusion/injection-related reactions (IRRs) and were categorised into the IRR group, while 2,268 patients who did not experience IRRs formed the non-IRR group.

Supplementary Table S1. Variance Inflation Factors (VIFs) for the final logistic regression model.

Variable	Variance inflation
Young age (*vs.* ≥65 years)	1.38
High CRP (*vs.* <2.8 mg/dL)	1.36
Diabetes mellitus	1.18
Secondary Sjögren's syndrome	1.05
Subcutaneous rheumatoid nodule	1.02
Interstitial lung disease	1.12
Prior use of methotrexate	5.05
Prior use of sulfasalazine	1.61
Prior use of leflunomide	2.08
Biologics that induced IRR or were used at enrolment (*vs.* infliximab)	3.94

VIF: variance inflation factor, CRP: C-reactive protein, IRR: infusion/injection-related reaction.